Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

100%(3 trials)

Phase Distribution

Ph phase_2

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

completed3100%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_2

Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)

NCT00310856

completedphase_2

Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

NCT00381615

completedphase_2

B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants

NCT00488683

Clinical Trials (3)

Showing 3 of 3 trials

NCT00310856Phase 2

Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)

Completed

NCT00381615Phase 2

Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Completed

NCT00488683Phase 2

B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants

Completed

All 3 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 3